Green Eric Mark's Form 4 filing
West Pharmaceutical Services IncWST · filed Dec 8, 2022
- Accession no.
- 0001562180-22-008148
- Filed
- Dec 8, 2022
- Trade date
- Dec 5, 2022
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $10.5M. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Green Eric MarkCIK 0001336007 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 5, 2022 | Common Stock | MOption exerciseAcquired | +50,000 | $57.38 | +$2,869,000 | 158,922.09 | Direct | |
| Dec 5, 2022 | Common Stock | SSaleDisposed | −6,746 | $236.95F3 | −$1,598,464.7 | 152,176.09 | Direct | |
| Dec 5, 2022 | Common Stock | SSaleDisposed | −9,408 | $237.67F4 | −$2,235,999.36 | 142,768.09 | Direct | |
| Dec 5, 2022 | Common Stock | SSaleDisposed | −6,312 | $238.83F5 | −$1,507,494.96 | 136,456.09 | Direct | |
| Dec 5, 2022 | Common Stock | SSaleDisposed | −10,752 | $239.70F6 | −$2,577,254.4 | 125,704.09 | Direct | |
| Dec 5, 2022 | Common Stock | SSaleDisposed | −9,682 | $240.73F7 | −$2,330,747.86 | 116,022.09 | Direct | |
| Dec 5, 2022 | Common Stock | SSaleDisposed | −1,100 | $241.46F8 | −$265,606 | 114,922.09 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 5, 2022 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 248,132 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $236.255 to $237.245, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $237.255 to $238.21, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $238.26 to $239.25, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $239.26 to $240.25, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $240.29 to $241.27, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $241.33 to $241.56, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Referenced by the price of 1 transaction in Table I.